Although we cannot directly evaluate the effect of minocycline-LYN binding in STAT3 inhibition and CRC metastasis suppression in CRC patients, these clinical data combined with our in vitro results support the notion that minocycline inhibits LYN-STAT3 signaling in CRC cells by direct LYN binding. The gene discussed is STAT3; the disease is colorectal carcinoma.